Audio

Community Oncology Podcast - Targeted therapies in multiple myeloma


 

Join community Oncology's Editor-in-Chief Dr. David Henry for an audio tour of the March issue, featuring Dr. Kenneth C. Anderson's review of targeted therapies in multiple myeloma, Dr. Stuart M. Lichtman's commentary on treating cancer in elderly patients, and Dr. Jame Abraham's Community Translation article on vemurafenib for melanoma with the BRAF V600E mutation.

Recommended Reading

Vorinostat Delivers Mixed Results in Multiple Myeloma
MDedge Hematology and Oncology
Phase II Results Continue to Support Carfilzomib in Myeloma
MDedge Hematology and Oncology
Less May Be More in Treating High-Risk Myeloma
MDedge Hematology and Oncology
FDA Approves Subcutaneous Bortezomib for Marketed Indications
MDedge Hematology and Oncology
JIA Cancer Rates Not Linked to Medication
MDedge Hematology and Oncology
Study: Myeloma Survival Gains, but QOL Slides
MDedge Hematology and Oncology
'Scrambler' Device Reduces Refractory Neuropathic Pain
MDedge Hematology and Oncology
Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
MDedge Hematology and Oncology
Is the US running too many T-cell lymphoma trials?
MDedge Hematology and Oncology
EMA recommends conditional approval of lymphoma drug
MDedge Hematology and Oncology